CME Group Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by CME Group Inc. on May 13, 2009. The report details the shareholder approval of amendments to three key equity and incentive compensation plans during the Company's Annual Meeting of Shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and compensation plan amendments rather than financial performance results.
Material Changes and Plan Amendments
- Omnibus Stock Plan: Shareholders approved amendments to this plan, which authorizes 8,045,975 shares. It covers stock options, restricted stock units, and performance awards for employees. The plan prohibits repricing and terminates on June 30, 2012.
- Director Stock Plan: Amendments were approved for this plan, authorizing 125,000 shares for non-executive directors. It includes cash, unrestricted shares, options, and restricted stock. The plan terminates no later than April 27, 2015.
- Bonus Plan: Amendments were approved for the Incentive Plan for Named Executive Officers. This plan uses cash earnings as a performance metric and has a maximum annual bonus of $5 million. It is designed to qualify under Section 162(m) of the Internal Revenue Code and expires on May 13, 2014.
- Share Freeze: In connection with these approvals, the Company undertook to freeze future grants representing approximately 900,000 shares under equity plans acquired from CBOT Holdings, Inc. and NYMEX Holdings, Inc.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or management commentary regarding market conditions. The primary risk noted is the dilution potential from the authorized shares in the Omnibus and Director plans, though the freeze on 900,000 shares from prior acquisitions mitigates some of this. All plans include change-in-control provisions that accelerate vesting.
Key Facts for Investor Verification
- Shareholder approval was obtained on May 13, 2009, for amendments to the Omnibus, Director, and Bonus plans.
- The Omnibus Stock Plan has 8,045,975 shares authorized.
- The Director Plan has 125,000 shares authorized.
- The Bonus Plan has a maximum annual payout of $5 million.
- Future grants of approximately 900,000 shares from acquired CBOT and NYMEX plans have been frozen.
- None of the amended plans allow for the repricing of existing awards.